On April 14, 2026 Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, reported it will release groundbreaking new data at the 2026 Annual American Association for Cancer Research (AACR) (Free AACR Whitepaper) meeting in San Diego, California. A major highlight of this year’s conference participation is the first clinical data disclosure from the MYTHIC Study (NCT04855656), a Phase I trial evaluating the combination of Debiopharm’s WEE1 inhibitor, zedoresertib (Debio 0123), with the PKMYT1 inhibitor lunresertib (Debio 2513) in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations. The oral presentation on April 19th 2026 will be given by Dr. Timothy A. Yap, a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center and Principal Investigator of the MYTHIC study.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Comprehensive pre-clinical results will also be presented for the MultiLINK ADC Technology Suite, showcasing the potential of novel dual payload antibody drug conjugates (ADCs) to enhance therapeutic efficacy. Two translational research posters will also be featured: the first highlighting the development of a Deep Learning-based "virtual" Cyclin E1 biomarker to predict protein overexpression in gynecological malignancies from H&E slides; the second unveiling how multiplexed spatial profiling and 3D cluster analysis are being used to reconcile RNASeq, mass spectrometry, and IHC data to refine therapeutic strategies for HER3 bispecific antibody and ADC programs.
"The first clinical results of the MYTHIC study mark an important milestone for the program. Early data readouts suggest strong synergistic activity between zedoresertib and lunresertib, with tumor regressions observed in patients," explained Esteban Rodrigo Imedio, Executive Medical Director, Oncology, Debiopharm
"Dual payload ADC technology has the potential to be a game changer for cancer patients. As patients need innovative solutions for hard-to-treat cancers, we hope that our dual payload research using MLINK Duo ADC linker technology will help us reshape how complex cancers are targeted and treated," expressed Antoine Attinger, Director, Translational Pharmacology, Debiopharm.
SESSION DETAILS
Session Type: Clinical Trials Plenary Session
AACR 2026 Oral Presentation
Debiopharm Compound
Title
Presenter
– Sun, April 19
– Time: 2:00 PM
– Hall H
zedoresertib (Debio 0123) & lunresertib (Debio 2513)
First data disclosure of the Phase I trial of the first-in-class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations
Dr. Timothy A. Yap, Medical Oncologist, University of Texas MD Anderson Cancer Center, Houston, TX
Session Title: Antibody Drug Conjugates and Linker Engineering 1
AACR 2026 Poster Presentation
Debiopharm Technology
Title
Author
– Mon, April 20
– Display: 9:00 AM – 12:00 PM
– Poster #: 1683
– Section: 12
MLINK Duo
Enhancing therapeutic efficacy and overcoming resistance with a novel dual payload antibody drug conjugate technology
Antoine Attinger et al., Translational Medicine,
Debiopharm International SA, Lausanne
Session Title: Digital Pathology 3
AACR 2026 Poster Presentation
Debiopharm Program
Title
Author
– Tue, April 21
– Display: 9:00 AM – 12:00 PM
– Poster #: 4155
– Section: 3
zedoresertib (Debio 0123)
Development of a virtual Cyclin E1 biomarker using Deep Learning from H&E slides for predicting Cyclin E1 overexpression in gynecological malignancy
Jeannette Fuchs et al.,
Translational Medicine, Debiopharm International SA, Lausanne
Session Title: Molecular Targets 2
AACR 2026 Poster Presentation
Debiopharm Program
Title
Author
– Tue, April 21
– Display: 2:00 PM – 5:00 PM
– Poster #: 5738
– Section: 13
HER3 ADCs
Beyond bulk: Resolving RNASeq/mass spectrometry/IHC discrepancies with multiplexed spatial profiling and 3D cluster analysis to refine HER3 (bs)Ab and (bs)ADC therapeutic strategies
Jeannette Fuchs et al.,
Translational Medicine, Debiopharm International SA, Lausanne
ABOUT DNA DAMAGE REPAIR (DDR)
When cells have damaged DNA, they must undergo a repair process known as DDR to survive. Cancer cells rely heavily on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, ultimately activating a programmed cell death process. DDR inhibitors such as zedoresertib (Debio 0123), Debiopharm’s WEE1 inhibitor, are currently being investigated in clinical and preclinical studies.
ABOUT PKMYT1 INHIBITION
Lunresertib (Debio 2513) is a first-in-class, oral PKMYT1 inhibitor designed to exploit specific genetic vulnerabilities in solid tumors, such as CCNE1 amplification. By targeting PKMYT1, the drug induces synthetic lethality, preventing cancer cells from repairing DNA damage and forcing them into programmed cell death. As the most advanced PKMYT1 inhibitor in clinical development, lunresertib has shown encouraging proof-of-concept results both as monotherapy and in combination therapies within the ongoing MYTHIC trial.
(Press release, Debiopharm, APR 14, 2026, View Source [SID1234664376])